These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 30098671)

  • 1. Comparing the ICERs in Medicine Reimbursement Submissions to NICE and PBAC-Does the Presence of an Explicit Threshold Affect the ICER Proposed?
    Wang S; Gum D; Merlin T
    Value Health; 2018 Aug; 21(8):938-943. PubMed ID: 30098671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996).
    George B; Harris A; Mitchell A
    Pharmacoeconomics; 2001; 19(11):1103-9. PubMed ID: 11735677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acceptance of health technology assessment submissions with incremental cost-effectiveness ratios above the cost-effectiveness threshold.
    Griffiths EA; Hendrich JK; Stoddart SD; Walsh SC
    Clinicoecon Outcomes Res; 2015; 7():463-76. PubMed ID: 26366099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10,000/QALY?
    Carroll C; Houten R; Boland A; Kaltenthaler E; Dickson R
    Value Health; 2018 Mar; 21(3):341-350. PubMed ID: 29566842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the National Institute for Health and Care Excellence Diagnostics Assessment Program Decisions: Incremental Cost-Effectiveness Ratio Thresholds and Decision-Modifying Factors.
    Chen G; Peirce V; Marsh W
    Value Health; 2020 Oct; 23(10):1300-1306. PubMed ID: 33032773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of QALY weights for QALY calculations: a review of industry submissions requesting listing on the Australian Pharmaceutical Benefits Scheme 2002-4.
    Scuffham PA; Whitty JA; Mitchell A; Viney R
    Pharmacoeconomics; 2008; 26(4):297-310. PubMed ID: 18370565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are cancer drugs less likely to be recommended for listing by the Pharmaceutical Benefits Advisory Committee in Australia?
    Chim L; Kelly PJ; Salkeld G; Stockler MR
    Pharmacoeconomics; 2010; 28(6):463-75. PubMed ID: 20465315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Governments Need Better Guidance to Maximise Value for Money: The Case of Australia's Pharmaceutical Benefits Advisory Committee.
    Carter D; Vogan A; Haji Ali Afzali H
    Appl Health Econ Health Policy; 2016 Aug; 14(4):401-407. PubMed ID: 26818196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.
    Clement FM; Harris A; Li JJ; Yong K; Lee KM; Manns BJ
    JAMA; 2009 Oct; 302(13):1437-43. PubMed ID: 19809025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia.
    Ball G; Levine MAH; Thabane L; Tarride JE
    Curr Oncol; 2022 Oct; 29(10):7624-7636. PubMed ID: 36290879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Justifying the source of external comparators in single-arm oncology health technology submissions: a review of NICE and PBAC assessments.
    Appiah K; Rizzo M; Sarri G; Hernandez L
    J Comp Eff Res; 2024 Feb; 13(2):e230140. PubMed ID: 38174576
    [No Abstract]   [Full Text] [Related]  

  • 12. The NICE cost-effectiveness threshold: what it is and what that means.
    McCabe C; Claxton K; Culyer AJ
    Pharmacoeconomics; 2008; 26(9):733-44. PubMed ID: 18767894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of PBAC submissions and outcomes for medicines (2010-2018).
    Lybrand S; Wonder M
    Int J Technol Assess Health Care; 2020 Jun; 36(3):224-231. PubMed ID: 32524923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis.
    Devlin N; Parkin D
    Health Econ; 2004 May; 13(5):437-52. PubMed ID: 15127424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accounting for inflation within NICE cost-effectiveness thresholds.
    Low V; Macaulay R
    Expert Rev Pharmacoecon Outcomes Res; 2022 Jan; 22(1):131-137. PubMed ID: 33980118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Büyükkaramikli NC; Blommestein HM; Riemsma R; Armstrong N; Clay FJ; Ross J; Worthy G; Severens J; Kleijnen J; Al MJ
    Pharmacoeconomics; 2017 Dec; 35(12):1211-1221. PubMed ID: 28656543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004.
    Harris AH; Hill SR; Chin G; Li JJ; Walkom E
    Med Decis Making; 2008; 28(5):713-22. PubMed ID: 18378939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the Quality of the Clinical Evidence in Submissions to the Australian Pharmaceutical Benefits Advisory Committee: Fit for Purpose?
    Wonder M; Dunlop S
    Value Health; 2015 Jun; 18(4):467-76. PubMed ID: 26091601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE RECOMMENDATIONS IN AUSTRALIA.
    Turkstra E; Bettington E; Donohue ML; Mervin MC
    Int J Technol Assess Health Care; 2017 Jan; 33(4):521-528. PubMed ID: 28703092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Key considerations in reimbursement decision-making for multiple sclerosis drugs in Australia.
    Phan YHL; De Abreu Lourenco R; Haas M; van der Linden N
    Mult Scler Relat Disord; 2018 Oct; 25():144-149. PubMed ID: 30077086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.